We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best healthcare stocks to buy according to hedge funds.
Resilience and Growth in the U.S. Healthcare Sector
Investing in healthcare equities is typically seen as protective during difficult economic times. This is because, even in times of financial hardship, people usually do not reduce their usage of prescription drugs or other necessary healthcare services. The Centers for Medicare and Medicaid Services (CMS) estimates that national healthcare expenditures would grow at an average rate of 5.6% between 2027 and 2032, with spending on healthcare expected to reach an estimated $4.8 trillion in 2023.
In America, the healthcare sector is booming. A new analysis showed that the Country’s healthcare spending rose by 7.5% in 2023, outpacing the nominal GDP growth rate of that year. A significant portion of the population, approximately 93.1% of Americans, had health insurance last year, which helped to drive up healthcare spending. The US government’s predicted 5.6% annual growth in healthcare spending between 2023 and 2032 is expected to surpass the 4.3% growth rate of the GDP.
Navigating Challenges and Opportunities in the Global Healthcare Market
The global healthcare industry is expanding, with McKinsey predicting profits to grow from $583 billion in 2022 to over $800 billion by 2027, at a 7% CAGR. Despite challenges in 2023 from labor shortages and inflation, 2024 is expected to recover, creating an attractive investment opportunity. AI investments in healthcare have surged, with $2.8 billion already invested in 2024 and expectations of over $11 billion by year-end. Deloitte’s 2024 outlook highlights high investor confidence, with AI poised to save $360 billion in U.S. healthcare over the next five years through advancements in patient care, diagnosis, and administration.
In 2023, the healthcare sector faced challenges as investors adjusted for higher interest rates, causing it to lag behind other sectors. However, GLP-1 drugs for weight loss significantly boosted some health companies’ income statements. The sector saw mixed performance, with some companies struggling due to tough comparisons after the COVID-19 vaccine and therapeutic revenues exceeded $100 billion in 2022. Rising interest rates also pressured biotechnology, and providers faced lingering COVID-19 impacts, although distributors improved with better fundamentals and opioid litigation resolutions. However, as fed’s easing of rate policy, with the last cut being that of 50 basis points, the healthcare market is expected to boost.
Our Methodology
For our methodology, we have ranked the best healthcare stocks to buy according to hedge funds based on their total number of hedge fund holders as of Q2 2024.
“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).”
A pharmacist filling a prescription for a complex drug developed by the company.
Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders: 69
Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse that specializes in developing and manufacturing innovative human therapeutics. At its core, Amgen focuses on creating biological medicines, which are complex proteins derived from living cells, to treat serious illnesses.
One of the primary catalysts for Amgen Inc. (NASDAQ:AMGN)’s growth is its pipeline of innovative medicines and the successful commercialization of existing products. In the first quarter of 2024, Amgen reported a 22% increase in total revenues to $7.4 billion compared to the same period in 2023. This growth was driven by a 25% increase in product sales volume, with ten products achieving double-digit volume growth, including Repatha, TEZSPIRE, and EVENITY. Additionally, the acquisition of Horizon Therapeutics contributed significantly to sales, adding $914 million from first-in-class medicines like TEPEZZA and KRYSTEXXA.
Amgen Inc. (NASDAQ:AMGN)’s revenue growth was strong, but profitability metrics were mixed: non-GAAP earnings per share (EPS) fell 1% to $3.96, while non-GAAP operating income was $3.1 billion. The dip in EPS was due to higher operating and interest expenses from the Horizon Therapeutics acquisition. Additionally, Amgen is entering the obesity treatment market, reporting positive interim results for its candidate MariTide (AMG 133), with topline data expected in late 2024.
As of Q2 2024, around 69 hedge fund holders held stakes in the stock with Citadel Investment Group being the largest stakeholder among the ones we tracked, with 1,432,100 shares worth $447,459,645. The stock holds a Moderate Buy rating based on 17 Wall Street analysts. In the last three months, 17 Wall Street analysts set a 12-month price target for Amgen at an average of $339.31, with a high of $381.00 and a low of $215.00, indicating a 1.00% change from the current price of $335.95.
Overall, AMGN ranks 9th among the best healthcare stocks to buy according to hedge funds. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than AMGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
